Client Alerts & Insights
Ohio Board of Pharmacy Answers Key Questions
October 18, 2021
Authored By:
Today, the State of Ohio Board of Pharmacy released the first set of Q&A responses for its second round of Medical Marijuana Dispensary Request for Applications. The Q&A responses can be found on the Medical Marijuana Control Program website. Over 200 questions were submitted ranging from questions on sources of capital, to site plan requirements. In the responses, the Board of Pharmacy has provided key guidance to applicants as they put together their applications for more Medical Marijuana Dispensary Licenses. This guidance will be instrumental to applicants as they navigate the application requirements and prepare the numerous required submissions to place their names in the hat for the license lottery.
One aspect of the application, the survey requirement, has generated a lot of questions from interested parties. In its responses, the Board of Pharmacy has made it clear that the survey “must be completed by a third-party, licensed professional.” They have further elaborated that there is no specific map required for the survey but that it must “contain all required information, be clearly legible and labeled, and may be divided into 8.4 by 11 inch sections.” Applicants will need to carefully review these Q&A responses to ensure that they are taking note of all guidance while preparing their application submissions.
The second Q&A period began on October 17, 2021 and will end on October 21, 2021. Questions may be submitted by emailing the medical marijuana control program. If Applicants have additional questions after reviewing the first Q&A responses, they will need to submit questions during the second Q&A period as this is the last opportunity they will have to receive guidance from the Board of Pharmacy.
If you need assistance with submitting questions to the Board of Pharmacy or with preparing your application for submission, the Benesch team is happy to assist. Reach out to one of our Regulated Industry experts to learn how we can help with your application.
Rob Zimmerman at rzimmerman@beneschlaw.com or 216.363.4437.
Kristopher J. Chandler at kchandler@beneschlaw.com or 614.223.9377.
Latest News
Medical First, Recreational Later? DOJ’s Cannabis Order and the Stakes Ahead
DOJ’s April 2026 order immediately moved FDA-approved and state-licensed medical cannabis to Schedule III, removing harsh tax penalties for medical operators, while leaving adult-use cannabis under stricter Schedule I controls pending further administrative review.
New Sentencing Guidelines for Economic Crimes Effective November 1, 2026
In March we reported on the U.S. Sentencing Commission’s proposed amendments to the Federal Sentencing Guidelines (the “Guidelines”). On April 16, 2026, the bipartisan United States Sentencing Commission (the “Commission”) voted unanimously to adopt that package of amendments, without modification.
Judicial Green Light: Court Upholds NLRB’s Cemex Decision
On April 21st, 2026, the U.S. Court of Appeals for the Ninth Circuit upheld the National Labor Relations Board’s (“NLRB”) decision in Cemex Construction Materials Pacific, LLC., reinforcing a significant shift in federal labor law governing union recognition and employer conduct during organizing campaigns.
The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here
The new LEAD Model, launching in 2027, is CMS’s next-generation value-based care framework for kidney care, integrating CKD and ESRD patients into standard ACOs with a 10-year benchmark period, new payment options and greater flexibility for nephrology-led organizations.